Cataya Bio (Shanghai) Co., Ltd. is a product company powered by an advanced engineering biology platform and biomanufacturing. We engineer microbes and develop clean fermentation processes to manufacture products of high purity, at low cost, and in a sustainable way. We strive to help the world to transition away from petroleum and address important global issues in environmental preservation, carbon emission and climate change.
We are a highly experienced team with our founders having a combined 40+ years of industrial experience in developing bio-based products. With world-class R&D and scale-up capabilities and a manufacturing plant under construction, we are building an end-to-end business going from technology development to manufacturing and commercialization.
Our board is comprised of dynamic and experienced leaders who embody the mission, guide the growth and shape the future of Cataya.
Dr. Liuyang Diao was Head of Shanghai R&D Center at Meihua Group, and Senior Director of R&D at BioSense before co-founding Cataya in 2021. Prior to that, he served as Project Manager at Shanghai R&D Center of Industrial Biotechnology. Dr. Diao has more than 10 years of experience in industrial biotechnology and successfully developed several robust and highly productive microbial strains and took them to biomanufacturing at commercial scale. He was selected as Outstanding Young Talent by Hebei Province in recognition of his excellence. Dr. Diao holds a Bachelor of Science degree in Biology from Anhui University and a Doctor of Philosophy degree in Microbiology from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Research Center Jülich, Germany.
Dr. Rui Wang has over 10 years of experience in bioanalytical research and applications for mass spectrometry-based omics technology. Prior to joining Cataya, Dr. Wang served as the Director of the Technical Services Department at Shanghai Applied Protein Technology Co., Ltd., which is a leader in providing mass spectrometry total solutions in China. During her tenure, she built product and operation teams and led the development of a range of proteomics and metabolomics analytical platforms, some of which received funding from the Shanghai governments. Dr. Wang holds a Ph.D. in Molecular Microbiology from Key Laboratory of Synthetic Biology, CAS, China and University of Tuebingen, Germany.
Mr. Yungang Huang has been at Source Code
Capital since 2017 and is currently a Partner. With over a decade of experience
in investment, Mr. Huang has a deep understanding of the evolution and impact
that new technologies have had on multiple industries and commerce. Mr. Huang
was nominated and chosen to join "The 2020 Midas Brink List" by
Forbes, "2020 F40 China Youth Investors" by PEdaily, and "2020
China's TOP20 Investors in Medical Sector" by 36Kr Media. Mr. Huang
graduated from Zhejiang University with a Bachelor’s Degree in Business
Management, and was one of the first recipients of Zhejiang University’s
Master’s Degree in Entrepreneurial Management. He has led investments in
outstanding enterprises including Cataya, METiS Pharmaceuticals, SiBionics,
Deep Potential, Nutshell Therapeutics, RELX Technology, Xianglu Technology, XYZ
Robotics, Kuaidi Dache, Liepin, etc.
Mr. Ning Xue graduated from Tsinghua University and Duke University. He is Head of Healthcare at Hengxu Capital. Mr. Xue has over ten-year experience in Healthcare sector. He led various investments such as Asieris Pharmaceuticals, Alphamab Oncology, RemeGen and Cataya Bio.
Reggie Zhang, Partner of Hongshan
Reggie focuses on seed and early stage technology investments and has over 13 years of experience in this area. He is interested in sectors such as enterprise services software, deep technologies, and consumer internet. Some of the investments he has made include Qingteng Cloud Security, Pony.ai, ShadowBot RPA, Megatronix Technology, XSKY, Trustfort, and iDreamsky etc. Before entering the venture investment field, Reggie worked in the chip and automotive industries, including Infineon China and TRW Automotive for years. Reggie graduated from Tsinghua University with a bachelor's and master's degree in automation and vehicle engineering.
We have established core capabilities in areas including strain engineering, enzyme engineering, miniaturized fermentation and data sciences to address current bottlenecks in engineering biology R&D.
We are building top-notch manufacturing facilities to rapidly scale up products in China and leveraging its best manufacturing infrastructure in the world for cost advantages.
We have a diverse pipeline of products targeting three highly growing markets - Personal Care, Food & Nutrition and Pharmaceutical Ingredients.
What Differentiates Us
End-to-end capabilities
A global company
Direct access to the largest market
Our values
To make the world better by accelerating
its transition to biomanufacturing.